These begin with alterations in SCFA signaling and subsequently diverge into bile acid-mediated pathways that modulate farnesoid X receptor (FXR) and Takeda G-protein-coupled receptor 5 (TGR5) activity [19 136]
The pathomechanisms of obesity-associated MASLD include lipotoxicity, inflammation, fibrogenesis, and carcinogenic risk [39], suggesting that combating obesity is a major objective in treating MASLD
What does dual agonist mean for Tirzepatide
Talk to your healthcare team or gastroenterologist if you notice differences from your normal stool, such as changes in consistency, color, frequency, or smell
If a patient has not achieved at least 5% weight loss by this point, the benefit-risk profile should be reevaluated
Eva (00:28:54): Plastic, plastic surgery and weight loss